When do you choose dose-dense chemotherapy v. q3 week therapy in advanced epithelial ovarian cancer?  

In our recent OGR, we suggested an approach to deciding which patients might be appropriate for considering the dose-dense regimen in the first line setting (Figure 2).  The dose-dense JGOG regimen was shown to confer an overall survival advantage in newly-diagnosed patients with advanced disea...